Healthcare Sales & Marketing Network News: Taiho Pharmaceutical

Searching News Database: Taiho Pharmaceutical

HSMN NewsFeed - 8 Jul 2021
Theolytics expands Series A financing and welcomes M Ventures as a new investor
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 1 Apr 2021
FDA Grants Breakthrough Therapy Designation for Taiho Oncology's Futibatinib for Treatment of Advanced Cholangiocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Jan 2021
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Jul 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 8 Jan 2018
STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 3 Jan 2018
Taiho Oncology Names Timothy Whitten President
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Apr 2016
Taiho's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in Asian Patients with Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Mar 2014
Taiho's Lonsurf(R) (trifluridine and tipiracil hydrochloride) Tablets Approved In Japan for Treatment of Advanced Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Feb 2013
MethylGene Announces the Appointment of Mark J. Gergen, as Executive Vice President and COO
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Sep 2009
FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Oct 2008
Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2008
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 17 Mar 2008
Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Feb 2008
Abraxis Bioscience Establishes Global Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Sep 2007
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Aug 2007
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Aug 2007
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Jun 2007
S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 7 additional stories matching:
Taiho Pharmaceutical
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.